Balanced Portfolio

Balanced Portfolio

Balanced Portfolio Recommendation: Switch PDN to URNM ETF

Given these dynamics, transitioning from Paladin Energy to the Uranium ETF (URNM) is recommended for those seeking to maintain exposure to the uranium sector while managing risk more effectively. URNM offers a diversified investment in uranium and nuclear energy stocks, thereby reducing the volatility associated with individual stock performances like Paladin’s. This move aligns with a strategy to capitalize on the thematic growth of the uranium sector while mitigating risk through diversification.

Balanced Portfolio

Balanced Portfolio Recommendation: Trim Take Profit – Elders (ELD)

For our trading strategy, we’re adjusting our position in Elders Limited (ELD) by reducing our allocation by 1% due to its recent impressive performance. Despite this adjustment, we will maintain a 2% allocation in ELD, recognizing the stock’s strong momentum. Additionally, the significant rainfall recently suggests the potential for continued positive performance, justifying our decision to retain a substantial investment in the company.

Balanced Portfolio

Balanced Portfolio Recommendation: Buy Worley Limited (WOR)

Adding WOR to Balanced Portfolio with a 3% allocation. WOR is a global company headquartered in Australia is a global provider of professional project and asset services in the energy, chemicals and resources sectors. As a knowledge-based service provider, they use their knowledge and capabilities to support the customers to reduce their emissions and move towards a low carbon future.

Balanced Portfolio

Balanced Portfolio Recommendation: Buy 1.5% Liontown Resources Ltd (LTR) & Buy 2% Mineral Resources Ltd MIN

It’s been a rocky ride for Lithium so far this year but through all the noise, we see quality buying opportunities in the space for the long term. Mining giants Gina Rinehart and Chris Ellison have long track records in running profitable mining operations in literally the most abundant mineral on the planet, Iron Ore and they are aggressively buying into the next mining boom of Lithium.

Balanced Portfolio

Balanced Portfolio Recommendation: Switch 2% ResMed (RMD) to Clinuvel Pharmaceuticals Ltd (CUV)

With the recent run in RMD we are looking to bank some profits here at $29 (+20%) while we see further upside in the stock, the risk that further developments in the GLP-1 space could derail this recent run. Particularly a study due from Eli Lily a maker of Zepbound in the next month.

We still prefer exposure in the healthcare space and are recommending a switch of our RMD allocation to Clinuvel (CUV) a skin disease treatment for sufferers of EPP. They are also in Phase 2 of a stroke treatment drug which is looking promising 

Scroll to Top